Corrigendum to “Dual regulatory effects of neferine on amyloid-β and tau aggregation studied by in silico, in vitro, and lab-on-a-chip technology” [Biomed. Pharmacother. 172 (2024) 1–14/116226] (Biomedicine & Pharmacotherapy (2024) 172, (S0753332224001070), (10.1016/j.biopha.2024.116226))

The authors regret “The correction includes a source of funding from the KHIDI (grant number: HI23C1263 to M.M.), which was unintentionally omitted in the original Research article due to an overlooked. The revised funding is included below.” The authors would like to apologise for any inconvenience caused. This research was funded by Basic Science Research Program of the National Research Foundation of Korea (NRF), which is funded by the Ministry of Science, ICT & Future Planning (NRF2018R1D1A3B07041059 and RS-2023-00240010 to M.M., NRF2022R1A6A3A13053190 to Y.N., RS-2023-00212388 to S.K. and RS-2023-00273557 to Y.H.P.) and was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HF21C0021 and HI23C1263 to M.M.). This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean Government (MSIP) (No. NRF2022R1I1A1A01072687 to I.P.).